Forest Laboratories, Glenmark, Teijin Ltd. deal

Glenmark's Glenmark S.A. subsidiary granted Teijin's Teijin Pharma Ltd. subsidiary exclusive Japanese development and commercialization rights to GRC 3886, a phosphodiesterase 4 ( PDE-4) inhibitor that has completed Phase I testing to treat chronic obstructive pulmonary disease (COPD) and asthma. Glenmark could receive up to $53 million in upfront and milestone payments. ...